The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

With economic uncertainty looming in the second half of 2025, as well as lingering inflationary pressures and potential interest rate changes, investors are becoming more cautious about where to ...

Johnson & Johnson (NYSE:JNJ) announced Wednesday that the European Commission has granted approval for its Darzalex ...

A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta ...

Johnson & Johnson reported strong second-quarter growth in its Jacksonville-based vision products business and expects more ...

How far can $25,000 get you? If you have a well-considered plan in place, you can actually turn your small account into a ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones. Companies had a lower bar to clear coming into the ...

Los Angeles Capital Management LLC dramatically increased its Johnson & Johnson holdings by 213.6% in Q1, now owning ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.